2-year PFS was significantly increased with ibrutinib vs BR but was not further improved by addition of rituximab.
Ongoing combination therapy achieved improved responses, including in older patients and across all high-risk groups, with 96% and 69% of patients achieving CR/CRi and BM MRD negativity, respectively, at 18 months.
In a combined analysis of KEYNOTE-013 and KEYNOTE-170, relapsed/refractory PMBCL patients who received pembrolizumab showed durable responses, with more than one half of patients alive at 1 year.
Combined BRAF and MEK inhibition was well tolerated and achieved a high rate of durable responses in this heavily pretreated patient population.
The rituximab biosimilar candidate PF-05280586 showed therapeutic equivalence and a similar safety profile vs reference rituximab-EU in previously untreated patients with CD20-positive low tumor burden follicular lymphoma.
Combination of rituximab with lenalidomide showed significantly improved disease control vs rituximab alone in this blinded study.
Addition of ibrutinib to obinutuzumab reduced risk of progression or death compared with chlorambucil plus obinutuzumab, including in patients with bulky disease and high-risk cytogenetics.
BTK inhibitor demonstrates durable efficacy and tolerability in patients with previously untreated CLL in this early-phase study.
Efficacy with R-CHOP x 4 → R x 2 was noninferior to R-CHOP x 6 with a decrease in the number of nonhematologic adverse events by approximately one third.
EFS, PFS, and OS were prolonged among patients younger than 60 years who were treated with ibrutinib + R-CHOP vs placebo + R-CHOP.
Frontline BV + CHP achieved superior PFS and OS vs standard CHOP with a manageable safety profile, leading to the recent FDA approval in this setting.
This primary analysis demonstrated a statistically significant improvement in both PFS and OS with first-line ibrutinib plus rituximab vs FCR in patients younger than 70 years of age.
PET-positive patients with limited-stage DLBCL who received PET-directed radiotherapy and ibritumomab tiuxetan after 3 cycles R-CHOP had similar 5-year PFS and OS rates as PET-negative patients who received an additional cycle of R-CHOP.
In a 2-year follow-up analysis of ZUMA-1, patients with refractory large B-cell lymphoma who received axicabtagene ciloleucel showed durable responses, including patients with high-risk disease.